Lumos Diagnostics (ASX:LDX) has signed an agreement with Henry Schein to distribute FebriDx in the US.
FebriDx is a rapid point-of-care respiratory test that delivers results 10 minutes from a fingerstick blood sample.
In July 2023, the US FDA cleared FebriDx as an aid in the diagnosis of bacterial acute respiratory infection and differentiation from non-bacterial etiology. The test has been cleared for use by healthcare professionals with patients presenting in urgent care or emergency care settings and is intended to be used in conjunction with clinical signs and symptoms, including other clinical and laboratory findings, to evaluate patients for acute respiratory infection.
Henry Schein, the world’s largest provider of healthcare solutions to office-based dental and medical practitioners, currently distributes the FebriDx test in the UK, Spain, Portugal, and the Netherlands.
“We are delighted that Henry Schein has expanded its distribution coverage for our FebriDx test to include the United States,” said Doug Ward, CEO and managing director of Lumos Diagnostics. “The US is the biggest commercial opportunity for FebriDx due to the routine use of point-of-care tests in standard clinical workflow and established reimbursement. We believe FebriDx has a unique role in ensuring that antibiotics are only given to patients who are likely to benefit from them. As Henry Schein has been an excellent distribution partner for Lumos in Europe, we are very excited to have them as our distribution partner in the world’s largest market for point-of-care testing”.